The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients.

ABSTRACT:

Background

Glioblastoma patients with hypermethylation of the O⁶-methylguanine-methyltransferase (MGMT) gene promoter have significantly improved survival when treated with temozolomide compared to patients with unmethylation of the MGMT promoter. However, the prognostic and predictive significance of partial MGMT promoter methylation is unclear.

Methods

The National Cancer Database was queried for patients newly diagnosed in 2018 with histopathologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma. The overall survival (OS) associated with MGMT promoter methylation status was assessed using multivariable Cox regression with Bonferroni correction for multiple testing (P < .008 was significant).

Results

T

SUBMITTER: Torre M 

PROVIDER: S-EPMC10037633 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature